Traders should monitor late Q2 2026 for topline Phase 3 data from the ABTECT-UC trial, which will be a major catalyst. The strong cash runway into Q4 2027 supports continued development, but profitability remains distant.
Price Chart
Executive Summary
Abivax reported full-year 2025 financial results with a net loss of €336.1 million, driven by higher R&D and G&A expenses, but strengthened its balance sheet with €530.4 million in cash after a $700.3 million public offering. The company remains on track to report topline Phase 3 data for obefazimod in ulcerative colitis in late Q2 2026, and appointed a new Chief Commercial Officer to prepare for potential commercialization.
Key Financial Metrics
Key Facts
- Net loss widened to €336.1 million in 2025 from €176.2 million in 2024
- Cash, cash equivalents, and short-term investments totaled €530.4 million as of December 31, 2025
- Raised $700.3 million (€597.2 million) in a public offering in July 2025
- DSMB found no new safety signals in the Phase 3 ABTECT-UC trial; topline results expected late Q2 2026
- Appointed Michael Nesrallah as Chief Commercial Officer to lead launch preparation for obefazimod
Financial Impact
Cash position increased by €372.5 million net of operations and financing; operating loss increased by €73.1 million year-over-year
Risk Factors
- Clinical trial results may not meet endpoints despite favorable safety data
- High cash burn rate: €161.1 million used in operations in 2025
- Dilution from the $700.3 million public offering may pressure shares if results disappoint
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3260837 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | Institutional Cluster | $130.00 $114.04 | ▼ −12.28% | ▼ −12.88% | $94.17 (−27.56%) |
Jul 2, 2026 13w ago | 6-K | $144.65 $124.33 | ▲ +14.05% | ▲ +13.63% | $94.17 (+34.90%) |
Jul 2, 2026 13w ago | 424B5 | $144.65 $124.33 | ▲ +14.05% | ▲ +13.63% | $94.17 (+34.90%) |
Jul 1, 2026 13w ago | Press Release | $132.56 $118.84 | ▲ +10.35% | ▲ +8.16% | $94.17 (+28.96%) |
Jun 29, 2026 13w ago | 6-K | $133.26 $128.00 | ▼ −3.95% | ▼ −2.92% | $94.17 (−29.33%) |
Jun 29, 2026 13w ago | Press Release | $133.26 $128.00 | ▼ −3.95% | ▼ −2.92% | $94.17 (−29.33%) |
May 22, 2026 18w ago | Press Release | $126.41 $94.01 | ▼ −25.63% | ▼ −23.68% | $94.17 (−25.50%) |
Mar 23, 2026 27w ago | Press Release | $110.17 $115.99 | ▲ +5.28% | ▼ −3.62% | $94.17 (−14.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access